Valuation: Nectar Lifesciences Limited

Market Cap 1.99B 21.29M 19.33M 17.85M 16.11M 30.41M 31.57M 215M 85.09M 1.07B 79.88M 78.2M 3.39B P/E 2025
-4.53x
P/E 2026 -0.69x
Enterprise Value 738M 7.9M 7.17M 6.63M 5.98M 11.28M 11.72M 79.84M 31.58M 398M 29.64M 29.02M 1.26B EV / Sales 2025
0.64x
EV / Sales 2026 -
Free-Float
44.17%
Yield 2025 *
-
Yield 2026 -
1 day-1.76%
1 week-2.99%
Current month-1.37%
1 month-9.04%
3 months-6.51%
6 months-18.74%
Current year-48.17%
1 week 10.02
Extreme 10.02
10.94
1 month 9.82
Extreme 9.82
11.61
Current year 9.3
Extreme 9.3
20.9
1 year 9.3
Extreme 9.3
22.4
3 years 9.3
Extreme 9.3
56.5
5 years 9.3
Extreme 9.3
56.5
10 years 7.1
Extreme 7.1
56.5
Manager TitleAgeSince
Director of Finance/CFO 68 13/11/2022
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 26/06/1995
Director/Board Member 69 10/02/2019
Director/Board Member 75 20/09/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/12/24 Buy 400,000 0.1784%
Change 5-day change 1-year change 3-year change Capi.($)
-1.76%-2.99%-26.62%-64.39% 21.29M
-1.13%-1.17%+38.55%+139.23% 1,261B
-1.36%-0.74%+39.64%+86.06% 671B
-0.59%-0.36%+25.14%+111.73% 518B
-0.76%+1.10%+41.43%+70.96% 387B
-0.75%-3.16%+54.39%+40.90% 353B
+0.08%-0.89%+26.00%+58.48% 300B
-0.18%-0.59%+1.55%+34.52% 283B
-0.95%-1.57%+34.01%+72.55% 248B
+1.60%-0.36%+37.21%+125.66% 211B
Average -0.59%-0.27%+27.13%+67.57% 423B
Weighted average by Cap. -0.74%-0.55%+34.97%+95.67%

Financials

2025 2026
Net sales 16.7B 179M 162M 150M 135M 255M 265M 1.81B 715M 9.01B 671M 657M 28.48B -
Net income -1.14B -12.17M -11.05M -10.2M -9.2M -17.38M -18.04M -123M -48.63M -613M -45.65M -44.69M -1.94B -2.93B -31.35M -28.46M -26.29M -23.72M -44.77M -46.49M -317M -125M -1.58B -118M -115M -4.99B
Net Debt 5.62B 60.18M 54.63M 50.47M 45.53M 85.95M 89.24M 608M 241M 3.03B 226M 221M 9.59B -1.25B -13.39M -12.16M -11.23M -10.13M -19.12M -19.86M -135M -53.52M -675M -50.24M -49.18M -2.13B
Projected Income Statement - Annual - Nectar Lifesciences Limited
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
111
Date Price Change Volume
18/11/26 ₹10.06 -1.76% 107,897
17/11/26 ₹10.24 -0.68% 49,952
16/11/26 ₹10.31 -3.28% 137,544
13/11/26 ₹10.66 +1.91% 113,443
12/11/26 ₹10.46 +0.87% 53,953
  1. Stock Market
  2. Stocks
  3. NECLIFE Stock